Mechanistic investigation of the hepatotoxicity and potential carcinogenicity of microcystin-LR, -LA, and -RR in the HepaRG cell line model
Archives of Toxicology · 2026
DOI: 10.1007/s00204-026-04458-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Toxicology, 2026. Verfasst von Enzo Zini Moreira Silva und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Federal University of Paraná (UFPR), Curitiba, PR, Brazil. Hauptthemen laut MEDLINE: Microcystins, Liver, Carcinogens, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesinstitut für Risikobewertung (BfR).
Abstract (Originalsprache)
Microcystins (MCs) are cyanobacterial toxins found in water and food and are suspected to pose significant health risks, particularly to the liver. To gain insight into the mechanisms of hepatotoxicity and the potential carcinogenicity of MCs, this study investigated the effects of MC-LR, -LA, and -RR (congeners differing in cellular uptake and detoxification efficiency) on PP2A activity, cell proliferation, and gene expression profiling focused on toxicity pathways and carcinogenesis in HepaRG cells. The three MCs similarly inhibited PP2A activity; however, only MC-LR and -LA significantly increased cell proliferation. Gene expression profiles (mRNA) revealed strong, similar treatment effects induced by MC-LR and -LA (R2 = 0.66), whereas -RR affected fewer genes, showing weak correlations with the other two congeners (-LRx-RR – R 2 = 0.31; -LAx-RR – R 2 = 0.06). Moreover, MC-LR and -LA, but not -RR, affected several liver-enriched toxicity pathways, which correlate most closely to hepatocellular/liver carcinoma, cholestasis, and fibrosis. All congeners altered carcinogenesis-related miRNA expression, but no consistent pattern was observed among them. Overall, the present findings reinforce the congener-specific toxicity of MCs, likely driven by differences in toxicokinetics among congeners. Furthermore, the findings indicate that MC-induced liver effects also involve PP2A-independent mechanisms, as MC-LR/-LA and -RR elicited markedly different biological responses despite comparable PP2A inhibition. Finally, the study demonstrates the applicability of the NAM-based approach for evaluating liver effects (hepatocytes) in the MC family and, as structurally different congeners were investigated, provides data that could be used for read-across and grouping.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics, Federal University of Paraná (UFPR), Curitiba, PR, Brazil.
- German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
- German Federal Institute for Risk Assessment (BfR), Berlin, Germany. Philip.Marx-Stoelting@bfr.bund.de.
Förderung
- Bundesinstitut für Risikobewertung (BfR)
Zitieren
APA
Silva, E. Z. M., Kiessig, S., Suciu, I., Mathias, C., de Lourdes Marzo-Solano, M., Pestana, C. B., Marx-Stoelting, P., & Leme, D. M. (2026). Mechanistic investigation of the hepatotoxicity and potential carcinogenicity of microcystin-LR, -LA, and -RR in the HepaRG cell line model. Archives of Toxicology. https://doi.org/10.1007/s00204-026-04458-0
Vancouver
Silva EZM, Kiessig S, Suciu I, Mathias C, de Lourdes Marzo-Solano M, Pestana CB, et al. Mechanistic investigation of the hepatotoxicity and potential carcinogenicity of microcystin-LR, -LA, and -RR in the HepaRG cell line model. Archives of Toxicology. 2026. doi:10.1007/s00204-026-04458-0
BibTeX
@article{Silva2026,
author = {Silva, Enzo Zini Moreira and Kiessig, Sahra and Suciu, Ilinca and Mathias, Carolina and de Lourdes Marzo-Solano, Marize and Pestana, Cynthia Bomfim and Marx-Stoelting, Philip and Leme, Daniela Morais},
title = {Mechanistic investigation of the hepatotoxicity and potential carcinogenicity of microcystin-LR, -LA, and -RR in the HepaRG cell line model},
journal = {Archives of Toxicology},
year = {2026},
doi = {10.1007/s00204-026-04458-0}
}
EUVIMED